SLC5A1 and type 2 diabetes mellitus: It was reported that metformin, a first-line agent for the treatment of type 2 diabetes, improves upper small intestine microbiota composition and restores the SGLT1-dependent glucose sensing to regulate glucose homeostasis (Wu et al., 2017; Bauer et al., 2018).